OOIR: Observatory of International Research

Papers

(The TQCC of American Journal of Hematology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
	441
The latest insights into rare blood disorders: Diagnosis and treatment strategies	413
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	254
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	219
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical	203
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	192
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	192
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	178
Introduction to American Journal of Hematology Supplement: Improving Initial Care for Acute GVHD Patients	134
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	123
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	120
Are veterans at increased risk of myeloproliferative neoplasms?	114
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	107
Teclistamab in patients with multiple myeloma and impaired renal function	102
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	100
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	99
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	98
Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal A	93
Autosomal Dominant Erythrocytosis Caused by Non‐Renal Erythropoietin ( EPO ) Due to EPO c	91
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	89
A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis	84
Peripheral Blood Erythrophagocytosis in Plasmodium falciparum Malaria	82
Polatuzumab Vedotin Combined With R ‐ ICE ( PolaR	79
Diagnosis and Management of Acute Chest Syndrome in Children With Sickle Cell Disease	79
Minutes Matter: An Audit of the Timeliness of Opioid Administration for Sickle Cell Disease Pain in the Emergency Department and Association With Disposition	77

The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	75
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	73
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	73
History of Thrombosis at High Altitude Associates With Increased Erythropoietin	70
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	63
Molecular and clinicopathologic characterization of pediatric histiocytoses	62
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	61
Clonal Hematopoiesis and Thrombosis	61
Predictors of Relapse and Post‐Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome‐Negative B‐ ALL	59
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	58
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	56
TEG and ROTEM : Technology and Clinical Applications, 2026 Update	54
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	53
Differential Prognosis and Transplant Strategies in CBF ‐ AML With	53
A First‐In‐Human Phase 1 Study of a Novel BCMA × CD3 Bispecific T Cell Engager	52
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	52
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	51
Table of Contents	50
Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series	49
Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?	49
Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic leukemia	48
	48
Rare circulating lymphoblasts with striking eosinophilia: A rare case of B‐lymphoblastic leukemia with PAX5::ZCCHC7	48
International Consensus Classification for myeloid neoplasms at‐a‐glance	48
Quick consults in hematology: Staging and treating immunoglobulin light chain (AL) amyloidosis	48
Alloantibody to Recombinant ADAMTS13 Reduces Clinical Efficacy in Congenital TTP : An Emerging The	48
Critical Blue‐Green Neutrophilic Inclusions in the Context of CD19 CAR ‐T Toxicity	46
Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex‐Stratified Analysis of the GIMEMA AML1310 Trial	44
Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource	44
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases	43
Hydroxyurea in pregnancy: Reframing the conversation	42
Persistent Sweet syndrome post‐hematopoietic stem cell transplantation heralding molecular relapse of myelofibrosis	42
A Transfusion Reaction due to Anti‐ER5 in a Hyposplenic β⁰ Thalassemia Major Patient	40
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (	39
Donor Age Matters for Haploidentical HCT Patients Even After Adjusting for HLA Factors: A Machine Learning Approach	39
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study	39
Genomic Proximity Mapping for Identification of Chromosomal Aberrations in Multiple Myeloma	38
Toward an improved understanding of hypomethylating agent and venetoclax therapies	38
Creative and Adaptive Solutions for Early Diagnosis of Sickle Cell Disease in Sub‐Saharan Africa	38
Impaired pro‐resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease	38
Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia	37
Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Tera	37
Triple A Plus ( AAA ⁺ ) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients	36
Table of Contents	36
Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries	36
A randomized double‐blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficien	36
Iron Overload and Anemia in Transferrin Immune Complex Disease, an Overlooked Monoclonal Gammopathy of Clinical Significance	36
Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real‐world retrospective multi‐institutional cohort	36
Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants	36
Real‐World Outcomes of Mycosis Fungoides and Site‐Specific Nodal Involvement: A Registry‐Based Study of 25 467 Patients	34

High‐Altitude Hypoxemia in Adults With Sickle Cell Disease ( SCD )	34
Lymphocyte Kinetics and Outcomes of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma With Out of Specification Products	33
A New Fetal Hemoglobin‐Related Phenotype in Sickle Cell Anemia	33
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients	33
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy	32
Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency	32
Performance Evaluation of a Novel Non‐Invasive Monitoring Device for At‐Home Neutropenia Detection in a Multicenter Cancer Cohort	32
POEMS syndrome: Update on diagnosis, risk‐stratification, and management	32
Interfollicular Plasmacytosis and Hyperplastic Germinal Centers in Idiopathic Multicentric Castleman Disease, Idiopathic Plasmacytic Lymphadenopathy Subtype	32
Avatrombopag in immune thrombocytopenia: A real‐world study of the Spanish ITP Group (GEPTI)	32
Neutrophilic eccrine hidradenitis in a pediatric patient with acute myeloid leukemia	31
Impact of Switching From Race‐Based to Race‐Neutral Spirometry Reference Equations in Children With Sickle Cell Anemia	31
Issue Information	31
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network ( EMN	31
Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia—aCML)	31
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring	31
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy	31
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors	30
Pearson syndrome	30
LLM Abstracts Supplement	30
Elevated MCHC reveals a Southeast Asian Ovalocytosis	29
A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo‐Gaucher Cells	29
The Diversity of Spiculated Erythrocytes	29
Moderate–severe beta‐thalassemia intermedia phenotype caused by sextuplicated alpha‐globin gene allele in two beta‐thalassemia carriers	28
Superior GVHD ‐Free, Relapse‐Free Survival for Haploidentical Transplant With PTCy Than Matched Un	28
The Safety and Efficacy of Commercial BCMA‐Directed CAR T‐Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma	27
Long‐term outcomes in light chain deposition disease‐analysis of a UK cohort	27
Combination of Biological Aging and Genetic Susceptibility Helps Identifying At‐Risk Population of Venous Thromboembolism: A Prospective Cohort Study of 394 041 Participants	27
Issue Information	27
Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study	26
Characterization of a Newly Discovered Non‐Coding Variant in the EPO Gene Identified in Two Unrelated Italian Pedigrees With Erythrocytosis	26
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies	26
Optimizing Asparaginase Treatment for Adolescent and Young Adult ( AYA ) Patients With Acute Lymphoblastic Leukemia: US	26
Myelokathexis in an 18‐year‐old male patient with severe neutropenia and lymphopenia	26
Distinctive Molecular Risk Factors Between MDS and MDS / AML	26
Hematologic Landscape of Adult Patients With Diamond‐Blackfan Anemia Syndrome	26
Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation	26
Six‐week low‐molecular‐weight heparin versus 12‐week warfarin for calf deep vein thrombosis: A randomized, prospective, open‐label study	25
Immune thrombocytopenia newly diagnosed during pregnancy: Outcome for mothers and neonates and comparison with chronic immune thrombocytopenia during pregnancy	25
Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With	25
Issue Information	25
Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front‐Line Daratumumab Lenalidomide and Dexamethasone	25
Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type	25
Advancing Sickle Cell Disease Treatment in Sub‐Saharan Africa: Challenges and Opportunities for Disease Modifying Therapies	25
Comparison of fludarabine‐based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry‐based study	24
Clinical Factors Associated With Catheter‐Related VTE in Patients Undergoing Hematopoietic Cell Transplantation: A Multi‐Center Study	24
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial	24
The prevalence and clinical outcomes of microangiopathic hemolytic anemia in patients with biopsy‐proven renal thrombotic microangiopathy	24
Ex Vivo IL ‐15‐Stimulated NK Cells as Adoptive Cell Therapy in Haploidentical Transplantation for	24
Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma	24
Innovation Alone Is Not Enough: The Urgent Need for Equitable Access in Thalassemia Care	24
Hemolytic anemia and macrothrombocytopenia: A lipid problem?	24
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?	24
Targeting PIEZO1 ‐ TMEM16F Coupling to Mitigate Sickle Cell Disease Complications	24
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management	23
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria	23
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion‐dependent β‐thalassemia	23
Myopathy related to chronic Graft‐Versus‐Host Disease: From clinic to histological & immunological characterization by imaging mass cytometry	23
	23
Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events	23
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management	23
Correction to “Efficacy and Safety of Early‐Start Deferiprone in Infants and Young Children With Transfusion‐Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Dou	23
Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept	23
Issue Information	23
Clinical Use of Eltrombopag and Avatrombopag in Pediatric ITP in China: A Real‐World Multicenter Retrospective Cohort Study	23
Prognostic Value of Hypoxemia for Acute Chest Syndrome in Adults With Sickle Cell Disease	23
Generating Off‐the‐Shelf Hematopoietic Stem Cells by “Stretching” Induced Pluripotent Stem Cells	23
Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia	23
Autoimmunity in sickle cell disease: Analysis of a large cohort of adult patients	22
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph‐positive leukemias	22
DNA Methylation Episignature as a Novel Diagnostic Tool for Diamond‐Blackfan Anemia Syndrome	22
Splenic Iron Overload Influence on Lumbar Spine BMD Reproducibility in β‐Thalassemia	22
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo‐Controlled Phase 2 DELTA	22
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial	22
Identification of a CAR‐Derived Clone by NGS‐Based MRD After Fully Human BCMA CAR T‐Cell Therapy in Multiple Myeloma	22
Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation	22
Reducing transfusion utilization for children with sickle cell anemia in sub‐Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial	22
Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial	21
Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B‐Cell Non‐Hodgkin Lymphoma	21
G‐ CSF for Mobilizing CD34 ⁺	21

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by	21
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing	21
Real World Study on the Best CPX ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation	21
Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T‐Cell Lymphoma	21
Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced‐Stage Extra‐Nodal NK /T‐Cell Lymphoma: A Multicenter Retrospect	20
Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha‐thalassemia	20
The MAGIC algorithm probability (MAP)‐guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial	20
SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers	20
Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma	20
Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma	20
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition	20
Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis	20
2025 update on clinical trials in immune thrombocytopenia	19
Acute hemolytic anemia after hematopoietic stem cell transplantation: An unusual invader	19
‘Phenoconversion’ in adult patients with β‐thalassemia	19
Table of Contents	19
Management of post‐autologous transplant relapse in patients with T‐cell lymphomas	19
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms	19
Issue Information	19
Issue Information	18
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria	18
Response to Ribeiro Jr. et al.	18
Treatment discontinuation in chronic myeloid leukemia: When, how, and why?	18
Complement biology for hematologists	18
Peripheral blood evidence of iron overload	18
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple	18
JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?	18
RETRACTION : A predictive model of herpes zoster after allogeneic hematopoietic stem cell transplantation: VZV reactiv	18
Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia	18
Hyperparathyroidism and the Hematologist	18
Mechanistic Consequences of Piezo1 Gain‐of‐Function Variants for Decreased Red Cell Survival in Hereditary Xerocytosis	18
Hospital Variations in Time‐To‐Crisis‐Resolution Among Children and Adolescents With Sickle Cell Disease	18
From Science to Solidarity: A Two‐Decade Collaboration in Thalassemia	18
Frequent bleeding symptoms associated with autoimmune acquired factor XIII/13 deficiency due to anti‐factor XIII A and B subunit antibodies	18
Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort	17
	17
Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma	17
Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice	17
Thalassemia enters a new age … And more lies ahead	17
Ontogeny and Natural History of Therapy‐Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic	17
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes	17
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myelo	17
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?	17
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA	17
ALK‐positive histiocytosis of external auditory canal in a 3‐year‐old boy	17
Real‐world implementation of the David–Carroll buprenorphine protocol for pain management in sickle cell disease	17
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management	17
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	17
Real‐World Outcomes in NPM1 ‐Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse	17
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia	17
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia	17
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or	17
	17
Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study	17
High incidence of malaria in patients with sickle cell disease	17
Issue Information	16
Recurrent Genomic Alterations in BCRi ‐Experienced CLL Patients Treated With Venetoclax: Extended	16
Correction to “Risk factors for severe infection and mortality in patients with COVID ‐19 in patients with multiple myeloma and <	16
Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia	16
Residual Cerebrovascular Morbidity Despite Treatment in Pediatric Sickle Cell Disease Highlights Opportunities for Earlier, Intensified Monitoring and Treatment	16
Fulminant intravascular hemolysis resulting from Clostridium perfringens infection	16
Incidence, Characteristics, and Management of Venous Thrombosis in Adult Patients With Immune Thrombocytopenia: Results From the Multicenter, Prospective Registry CARMEN‐France	16
Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable	16
Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study	16
Crystal‐storing lymphocytosis	16
Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study	16
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases	16
Prevalence and Risk Factors for Venous Thromboembolism in People With Inherited Bleeding Disorders: An ATHNdataset Study	16
DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1	16
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment	16
Increased risk of venous thromboembolism in patients with gastrointestinal disorders	16
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications	16
Correction to “Analysis of 60 Patients with Relapsed or Refractory T‐cell Acute Lymphoblastic Leukemia and T‐cell Lymphoblastic Lymphoma Treated with CD7	16
Changing hemostatic management in post‐partum hemorrhage	15
The prognostic value of blood cellular indices in pulmonary embolism	15
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring	15
Poor Engraftment After Posttransplant Cyclophosphamide Graft‐Versus‐Host Disease Prophylaxis in Patients With Myelofibrosis	15
Issue Information	15
Classic Hairy Cell Leukemia With MAP2K1 Mutation: Diagnosis and Targeted Therapy	15
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria	15
Identification of Clinical Sub‐Phenotypes of Sickle Cell Disease Using Latent Class Analysis	15
p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53 ‐Mu	15
COVID‐19 mRNA vaccine‐associated cerebral venous thrombosis: Rare adverse event or coincidence?	15
Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta‐analysis	15
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort	15
The Care and Cure of the Leukemias in 2026	15
Ferric Carboxymaltose (FCM)–Associated Hypophosphatemia (HPP): A Systematic Review	15
Clinical Predictors of Response in Chronic Graft‐Versus‐Host Disease: Results From the “Predicting the Quality of Response to Specific Treatments ( PQRST	15
Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era	15
Artificial intelligence generated leukemia cell images	14
Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan	14
Rocky Mountain Spotted Fever, a Lymphoma Mimic on Peripheral Blood Smear	14
	14
Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies	14
Hemolysis and Acquired Pyruvate Kinase Deficiency in a Child With a Malignant Myeloid Disorder	14